205 related articles for article (PubMed ID: 36238279)
1. Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade.
He L; Jin M; Jian D; Yang B; Dai N; Feng Y; Xiao H; Wang D
Front Immunol; 2022; 13():955187. PubMed ID: 36238279
[TBL] [Abstract][Full Text] [Related]
2. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
[TBL] [Abstract][Full Text] [Related]
3. FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients.
Xu K; Yin X; Zhou B; Zheng X; Wang H; Chen J; Cai X; Gao H; Xu X; Wang L; Shen L; Guo T; Zheng S; Li B; Shao Y; Wang J
Cancer Lett; 2023 May; 562():216145. PubMed ID: 36997107
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
5. A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.
Takahashi H; Watanabe H; Hashimura M; Matsumoto T; Yokoi A; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Saegusa M
J Pathol Clin Res; 2022 Sep; 8(5):458-469. PubMed ID: 35762092
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H; Tsukada Y; Inamori K; Togashi Y; Koyama S; Kotani D; Fukuoka S; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Wakabayashi M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Suzuki Y; Sato A; Nishikawa H; Ito M; Yoshino T
Clin Cancer Res; 2022 Mar; 28(6):1136-1146. PubMed ID: 35063964
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer.
Liu C; Wang P; Sun Y; Dou X; Hu X; Zou W; Sun Y; Hu Q; Yue J
Front Oncol; 2022; 12():756811. PubMed ID: 35530332
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19-9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Zheng Z; Wang X; Lu X; Huang Y; Chi P
Colorectal Dis; 2021 Sep; 23(9):2320-2330. PubMed ID: 33900006
[TBL] [Abstract][Full Text] [Related]
11. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
12. The implications from the interplay of neoadjuvant chemoradiotherapy and the immune microenvironment in rectal cancer.
Shi M; Chen Y; Ji D
Future Oncol; 2022 Sep; 18(28):3229-3244. PubMed ID: 36017694
[TBL] [Abstract][Full Text] [Related]
13. [Predictive value of combination of MRI tumor regression grade and apparent diffusion coefficient for pathological complete remission after neoadjuvant treatment of locally advanced rectal cancer].
Xu N; Huang FC; Li WL; Luan X; Jiang YM; He B
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):359-365. PubMed ID: 33878826
[No Abstract] [Full Text] [Related]
14. Impact of total neoadjuvant therapy consisting of consolidation chemotherapy on locally advanced rectal cancer survival.
Zhang H; Li G; Cao K; Zhai Z; Wei G; Qu H; Wang Z; Han J
Int J Colorectal Dis; 2022 Jul; 37(7):1657-1668. PubMed ID: 35716183
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
[TBL] [Abstract][Full Text] [Related]
16. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Huang MY; Huang CW; Wang JY
Kaohsiung J Med Sci; 2020 Mar; 36(3):152-159. PubMed ID: 31814296
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
[TBL] [Abstract][Full Text] [Related]
19. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
Crimì F; Capelli G; Spolverato G; Bao QR; Florio A; Milite Rossi S; Cecchin D; Albertoni L; Campi C; Pucciarelli S; Stramare R
Radiol Med; 2020 Dec; 125(12):1216-1224. PubMed ID: 32410063
[TBL] [Abstract][Full Text] [Related]
20. Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer.
Xiao W; Luo H; Yao Y; Wang Y; Liu S; Sun R; Chen G
Front Immunol; 2023; 14():1149122. PubMed ID: 37033988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
